Stefan Barth

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2198085/publications.pdf

Version: 2024-02-01

179	3,669	147801	214800
papers	citations	31 h-index	47 g-index

188	188	188	3872
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Antibodyâ€“siRNA conjugates (ARC): Emerging siRNA drug formulation. Medicine in Drug Discovery, 2022, 15, 100128.	4.5	12
2	Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B-cell-type diffuse large B-cell lymphoma. Haematologica, 2021, 106, 2224-2232.	3.5	11
3	Recent advances in immunotherapies against infectious diseases. Immunotherapy Advances, 2021, 1, .	3.0	28
4	Antibody-siRNA conjugates (ARCs) using multifunctional peptide as a tumor enzyme cleavable linker mediated effective intracellular delivery of siRNA. International Journal of Pharmaceutics, 2021, 606, 120940.	5.2	18
5	Isolation and light chain shuffling of a Plasmodium falciparum AMA1-specific human monoclonal antibody with growth inhibitory activity. Malaria Journal, 2021, 20, 37.	2.3	4
6	Desensitization of metastatic melanoma cells to therapeutic treatment through repeated exposure to dacarbazine. Journal of Photochemistry and Photobiology B: Biology, 2020, 211, 111982.	3.8	10
7	Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma. Biomedicines, 2020, 8, 327.	3.2	9
8	Cell-penetrating peptide enhanced insulin buccal absorption. International Journal of Pharmaceutics, 2020, 584, 119469.	5.2	16
9	Advances in epidermal growth factor receptor specific immunotherapy: lessons to be learned from armed antibodies. Oncotarget, 2020, 11, 3531-3557.	1.8	13
10	Antibody-Based Targeted Interventions for the Diagnosis and Treatment of Skin Cancers. Anti-Cancer Agents in Medicinal Chemistry, 2020, 21, 162-186.	1.7	2
11	Using the SNAP-Tag technology to easily measure and demonstrate apoptotic changes in cancer and blood cells with different dyes. PLoS ONE, 2020, 15, e0243286.	2.5	1
12	One-step site-specific antibody fragment auto-conjugation using SNAP-tag technology. Nature Protocols, 2019, 14, 3101-3125.	12.0	19
13	Applications of SNAPâ€tag technology in skin cancer therapy. Health Science Reports, 2019, 2, e103.	1.5	4
14	Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Oncotarget, 2019, 10, 897-915.	1.8	8
15	Elimination of HER3â€expressing breast cancer cells using aptamerâ€siRNA chimeras. Experimental and Therapeutic Medicine, 2019, 18, 2401-2412.	1.8	7
16	Abstract 3732: Targeted photodynamic therapy enhances the therapeutic efficacy of combination therapy (PDT and chemotherapy) on chemoresistant melanoma cells. , 2019, , .		1
17	Abstract 3732: Targeted photodynamic therapy enhances the therapeutic efficacy of combination therapy (PDT and chemotherapy) on chemoresistant melanoma cells. , 2019, , .		0
18	Control of mechanical pain hypersensitivity in mice through ligand-targeted photoablation of TrkB-positive sensory neurons. Nature Communications, 2018, 9, 1640.	12.8	93

#	Article	IF	Citations
19	Elimination of different leukaemia subtypes using novel <scp>CD</scp>89â€specific human cytolytic fusion proteins. British Journal of Haematology, 2018, 183, 313-317.	2.5	7
20	Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases. Frontiers in Microbiology, 2018, 9, 3158.	3.5	66
21	Simultaneous and Independent Dual Site-Specific Self-Labeling of Recombinant Antibodies. Bioconjugate Chemistry, 2018, 29, 3586-3594.	3.6	9
22	Characterization of new anti-IL-6 antibodies revealed high potency candidates for intracellular cytokine detection and specific targeting of IL-6 receptor binding sites. European Cytokine Network, 2018, 29, 59-72.	2.0	1
23	Updates in the Development of ImmunoRNases for the Selective Killing of Tumor Cells. Biomedicines, 2018, 6, 28.	3.2	35
24	Human Granzyme B Based Targeted Cytolytic Fusion Proteins. Biomedicines, 2018, 6, 72.	3.2	24
25	Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach. Pharmaceutical Research, 2017, 34, 696-703.	3.5	20
26	SNAP-Tag Technology: A Promising Tool for Ex Vivo Immunophenotyping. Molecular Diagnosis and Therapy, 2017, 21, 315-326.	3.8	1
27	Recombinant Immunotoxins for Chronic Inflammatory Disease. Milestones in Drug Therapy, 2017, , 131-150.	0.1	0
28	Next Generation Antibody Drug Conjugates (ADCs) and Immunotoxins. Milestones in Drug Therapy, 2017, , .	0.1	3
29	Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Transfusion Medicine and Hemotherapy, 2017, 44, 303-310.	1.6	10
30	Novel PSCA targeting scFv-fusion proteins for diagnosis and immunotherapy of prostate cancer. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2025-2038.	2.5	12
31	Efficient targeting of CD13 on cancer cells by the immunotoxin scFv13â€"ETAâ€² and the bispecific scFv [13xds16]. Journal of Cancer Research and Clinical Oncology, 2017, 143, 2159-2170.	2.5	10
32	Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. OncoTargets and Therapy, 2017, Volume 10, 3313-3327.	2.0	19
33	Designing the Sniper: Improving Targeted Human Cytolytic Fusion Proteins for Anti-Cancer Therapy via Molecular Simulation. Biomedicines, 2017, 5, 9.	3.2	8
34	CSPG4: A Target for Selective Delivery of Human Cytolytic Fusion Proteins and TRAIL. Biomedicines, 2017, 5, 37.	3.2	17
35	CD64: An Attractive Immunotherapeutic Target for M1-type Macrophage Mediated Chronic Inflammatory Diseases. Biomedicines, 2017, 5, 56.	3.2	79
36	Restoration of DAP Kinase Tumor Suppressor Function: A Therapeutic Strategy to Selectively Induce Apoptosis in Cancer Cells Using Immunokinase Fusion Proteins. Biomedicines, 2017, 5, 59.	3.2	10

#	Article	IF	Citations
37	Generation of an artificial human B cell line test system using Transpo-mAbTM technology to evaluate the therapeutic efficacy of novel antigen-specific fusion proteins. PLoS ONE, 2017, 12, e0180305.	2.5	4
38	Human MAP Tau Based Targeted Cytolytic Fusion Proteins. Biomedicines, 2017, 5, 36.	3.2	12
39	Immunotoxins. , 2017, , 1-4.		0
40	Immunotoxins. , 2017, , 2239-2242.		0
41	Abstract 4576: Targeted human cytolytic fusion proteins: an update. , 2017, , .		0
42	Development of a Competitive Cystatin C-Specific Bioassay Suitable for Repetitive Measurements. PLoS ONE, 2016, 11, e0147177.	2.5	0
43	SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments. Bioconjugate Chemistry, 2016, 27, 1931-1941.	3.6	8
44	Engineered human angiogenin mutations in the placental ribonuclease inhibitor complex for anticancer therapy: Insights from enhanced sampling simulations. Protein Science, 2016, 25, 1451-1460.	7.6	11
45	A Monoclonal Antibody That Discriminates Between SNAP-Tagged and CLIP-Tagged Proteins. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2016, 35, 141-147.	1.6	2
46	Characterization of a novel inhibitory human monoclonal antibody directed against Plasmodium falciparum Apical Membrane Antigen 1. Scientific Reports, 2016, 6, 39462.	3.3	30
47	A Novel Recombinant Anti-CD22 Immunokinase Delivers Proapoptotic Activity of Death-Associated Protein Kinase (DAPK) and Mediates Cytotoxicity in Neoplastic B Cells. Molecular Cancer Therapeutics, 2016, 15, 971-984.	4.1	6
48	The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Cancer Letters, 2016, 381, 323-330.	7.2	36
49	A novel approach for targeted elimination of CSPG4â€positive tripleâ€negative breast cancer cells using a MAP tauâ€based fusion protein. International Journal of Cancer, 2016, 139, 916-927.	5.1	28
50	Novel fusion proteins for the antigen-specific staining and elimination of B cell receptor-positive cell populations demonstrated by a tetanus toxoid fragment C (TTC) model antigen. BMC Biotechnology, 2016, 16, 18.	3.3	6
51	Acquired immune responses to three malaria vaccine candidates and their relationship to invasion inhibition in two populations naturally exposed to malaria. Malaria Journal, 2016, 15, 65.	2.3	3
52	Fully human MAPâ€fusion protein selectively targets and eliminates proliferating CD64 + M1 macrophages. Immunology and Cell Biology, 2016, 94, 470-478.	2.3	12
53	Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model. Cancer Letters, 2016, 372, 201-209.	7.2	32
54	A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1003-1011.	2.5	29

#	Article	IF	Citations
55	A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor. Cancer Letters, 2016, 374, 229-240.	7.2	35
56	Targeting c-kit receptor in neuroblastomas and colorectal cancers using stem cell factor (SCF)-based recombinant bacterial toxins. Applied Microbiology and Biotechnology, 2016, 100, 263-277.	3.6	8
57	Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand. Oncotarget, 2016, 7, 54925-54936.	1.8	24
58	CD64-directed microtubule associated protein tau kills leukemic blastsex vivo. Oncotarget, 2016, 7, 67166-67174.	1.8	10
59	Ribosome-Inactivating Proteins. , 2016, , 4083-4087.		0
60	The Fcâ€alpha receptor is a new target antigen for immunotherapy of myeloid leukemia. International Journal of Cancer, 2015, 137, 2729-2738.	5.1	15
61	Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. Malaria Journal, 2015, 14, 276.	2.3	20
62	Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities. Journal of Cancer Research and Clinical Oncology, 2015, 141, 2079-2095.	2.5	37
63	Novel angiogenin mutants with increased cytotoxicity enhance the depletion of pro-inflammatory macrophages and leukemia cells ex vivo. Cancer Immunology, Immunotherapy, 2015, 64, 1575-1586.	4.2	11
64	Heat-Transfer-Method-Based Cell Culture Quality Assay through Cell Detection by Surface Imprinted Polymers. Langmuir, 2015, 31, 2043-2050.	3.5	29
65	Improving the sensitivity of the heatâ€transfer method (HTM) for cancer cell detection with optimized sensor chips. Physica Status Solidi (A) Applications and Materials Science, 2015, 212, 1320-1326.	1.8	13
66	Antimalarial Activity of Granzyme B and Its Targeted Delivery by a Granzyme Bâ€“Single-Chain Fv Fusion Protein. Antimicrobial Agents and Chemotherapy, 2015, 59, 669-672.	3.2	21
67	Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody. Malaria Journal, 2015, 14, 50.	2.3	17
68	In vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cells. Journal of Cancer Research and Clinical Oncology, 2015, 141, 1049-1061.	2.5	17
69	Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia. MAbs, 2015, 7, 390-402.	5.2	18
70	Phage display-based on-slide selection of tumor-specific antibodies on formalin-fixed paraffin-embedded human tissue biopsies. Immunology Letters, 2015, 166, 65-78.	2.5	12
71	Targeted killing of rhabdomyosarcoma cells by a MAP-based human cytolytic fusion protein. Cancer Letters, 2015, 365, 149-155.	7.2	10
72	Angiogenin Mutants as Novel Effector Molecules For the Generation of Fusion Proteins With Increased Cytotoxic Potential. Journal of Immunotherapy, 2015, 38, 85-95.	2.4	12

#	Article	IF	Citations
73	Engineered Versions of Granzyme B and Angiogenin Overcome Intrinsic Resistance to Apoptosis Mediated by Human Cytolytic Fusion Proteins. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 185-219.	0.1	4
74	Targeting CD64 mediates elimination of M1 but not M2 macrophages in vitro and in cutaneous inflammation in mice and patient biopsies. MAbs, 2015, 7, 853-862.	5.2	56
75	BARs (B -cell receptor a ntigens for r everse targeting): A Novel and Ultimately Specific Treatment Concept for B-Cell Neoplasms. Blood, 2015, 126, 3995-3995.	1.4	0
76	Absorption Reconstruction Improves Biodistribution Assessment of Fluorescent Nanoprobes Using Hybrid Fluorescence-mediated Tomography. Theranostics, 2014, 4, 960-971.	10.0	46
77	Recombinant H22(scFv) blocks CD64 and prevents the capture of anti-TNF monoclonal antibody. MAbs, 2014, 6, 1283-1289.	5.2	5
78	Plasmonic flow-through biosensor using a polymeric substrate. Journal of Micromechanics and Microengineering, 2014, 24, 034001.	2.6	3
79	Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases. Antibodies, 2014, 3, 92-115.	2.5	7
80	Cloning Murine Antibody V-genes with Non-degenerate Primers and Conversion to a Recombinant Antibody Format. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2014, 33, 369-377.	1.6	6
81	Systematic improvement of lentivirus transduction protocols by antibody fragments fused to VSV-G as envelope glycoprotein. Biomaterials, 2014, 35, 4204-4212.	11.4	10
82	Targetedex vivoreduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. International Journal of Cancer, 2014, 135, 1497-1508.	5.1	24
83	Human microtubuleâ€associated protein tau mediates targeted killing of <scp>CD</scp>30⁺ lymphoma cells in vitro and inhibits tumour growth in vivo. British Journal of Haematology, 2014, 164, 251-257.	2.5	16
84	A CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissues. Cancer Letters, 2014, 352, 228-235.	7.2	22
85	EpCAM-Selective Elimination of Carcinoma Cells by a Novel MAP-Based Cytolytic Fusion Protein. Molecular Cancer Therapeutics, 2014, 13, 2194-2202.	4.1	20
86	CD30 as a Therapeutic Target for Lymphoma. BioDrugs, 2014, 28, 181-209.	4.6	32
87	Assessment of the neutrophilic antibody-dependent respiratory burst (ADRB) response toPlasmodium falciparum. Journal of Leukocyte Biology, 2014, 96, 1131-1142.	3.3	35
88	Heat-Transfer Resistance Measurement Method (HTM)-Based Cell Detection at Trace Levels Using a Progressive Enrichment Approach with Highly Selective Cell-Binding Surface Imprints. Langmuir, 2014, 30, 3631-3639.	3.5	26
89	Ribosome-Inactivating Proteins. , 2014, , 1-5.		0
90	Immunotoxins. , 2014, , 1-4.		0

#	Article	IF	Citations
91	An Aptamerâ€“siRNA Chimera Silences the Eukaryotic Elongation Factor 2 Gene and Induces Apoptosis in Cancers Expressing Î±vÎ²3 Integrin. Nucleic Acid Therapeutics, 2013, 23, 203-212.	3.6	26
92	267. Cytokine, 2013, 63, 306.	3.2	1
93	A monoclonal antibody for the detection of SNAP/CLIP-tagged proteins. Immunology Letters, 2013, 150, 69-74.	2.5	7
94	Granzyme M as a novel effector molecule for human cytolytic fusion proteins: CD64-specific cytotoxicity of Gm-H22(scFv) against leukemic cells. Cancer Letters, 2013, 341, 178-185.	7.2	23
95	Targeted Delivery of Dendritic Polyglycerolâ€“Doxorubicin Conjugates by scFv-SNAP Fusion Protein Suppresses EGFR⁺ Cancer Cell Growth. Biomacromolecules, 2013, 14, 2510-2520.	5.4	62
96	Species-Dependent Functionality of the Human Cytolytic Fusion Proteins Granzyme B-H22(scFv) and H22(scFv)-Angiogenin in Macrophages. Antibodies, 2013, 2, 9-18.	2.5	12
97	Improving the Therapeutic Potential of Human Granzyme B for Targeted Cancer Therapy. Antibodies, 2013, 2, 19-49.	2.5	21
98	Targeting the fetal acetylcholine receptor in rhabdomyosarcoma. Expert Opinion on Therapeutic Targets, 2013, 17, 127-138.	3.4	8
99	Efficacy of an adapted granzyme B-based anti-CD30 cytolytic fusion protein against PI-9-positive classical Hodgkin lymphoma cells in a murine model. Blood Cancer Journal, 2013, 3, e106-e106.	6.2	28
100	Microtubule-associated protein tau facilitates the targeted killing of proliferating cancer cells in vitro and in a xenograft mouse tumour model in vivo. British Journal of Cancer, 2013, 109, 1570-1578.	6.4	33
101	Editorial (The SNAP-tag Technology â€“ A Versatile Tool with many Applications). Current Pharmaceutical Design, 2013, 19, 5404-5405.	1.9	1
102	SNAP-Tag Technology: A Powerful Tool for Site Specific Conjugation of Therapeutic and Imaging Agents. Current Pharmaceutical Design, 2013, 19, 5437-5442.	1.9	26
103	SNAP-tag based Agents for Preclinical In Vitro Imaging in Malignant Diseases. Current Pharmaceutical Design, 2013, 19, 5429-5436.	1.9	18
104	SNAP-Tag Technology: A General Introduction. Current Pharmaceutical Design, 2013, 19, 5406-5413.	1.9	29
105	Abstract B240: Novel protein fusion toxins targeting c-kit positive neuroendocrine tumors.. , 2013, , .		0
106	Labeling of Anti-MUC-1 Binding Single Chain Fv Fragments to Surface Modified Upconversion Nanoparticles for an Initial in Vivo Molecular Imaging Proof of Principle Approach. International Journal of Molecular Sciences, 2012, 13, 4153-4167.	4.1	9
107	Macrophage-Targeted Therapy: CD64-Based Immunotoxins for Treatment of Chronic Inflammatory Diseases. Toxins, 2012, 4, 676-694.	3.4	39
108	Generation and imaging of patient customized implants. Biomedizinische Technik, 2012, 57, .	0.8	0

#	Article	IF	Citations
109	Reduction of activated macrophages after ischaemia-reperfusion injury diminishes oxidative stress and ameliorates renal damage. Nephrology Dialysis Transplantation, 2012, 27, 3149-3155.	0.7	12
110	In vivo imaging of immunotoxin treatment using Katushka-transfected A-431 cells in a murine xenograft tumour model. Cancer Immunology, Immunotherapy, 2012, 61, 1617-1626.	4.2	20
111	Short-chain fluorescent tryptophan tags for on-line detection of functional recombinant proteins. BMC Biotechnology, 2012, 12, 65.	3.3	19
112	Design of human granzyme B variants resistant to serpin B9. Proteins: Structure, Function and Bioinformatics, 2012, 80, 2514-2522.	2.6	24
113	Cetuximab induces mitochondrial translocalization of EGFRvIII, but not EGFR: involvement of mitochondria in tumor drug resistance?. Tumor Biology, 2012, 33, 85-94.	1.8	31
114	Directed Covalent Immobilization of Fluorescently Labeled Cytokines. Bioconjugate Chemistry, 2011, 22, 1210-1220.	3.6	18
115	SNAP-Tag Technology Mediates Site Specific Conjugation of Antibody Fragments with a Photosensitizer and Improves Target Specific Phototoxicity in Tumor Cells. Bioconjugate Chemistry, 2011, 22, 2487-2495.	3.6	66
116	Generation of recombinant antibody fragments that target canine dendritic cells by phage display technology. Veterinary and Comparative Oncology, 2011, 9, 183-195.	1.8	10
117	Quantitative measurement of human anti-HCV Core immunoglobulins on an electrical biochip platform. Biosensors and Bioelectronics, 2011, 26, 1895-1901.	10.1	11
118	In vivo efficacy of the recombinant antiâ€CD64 immunotoxin H22(scFv)â€ETAâ€² in a human acute myeloid leukemia xenograft tumor model. International Journal of Cancer, 2011, 129, 1277-1282.	5.1	32
119	Rapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion protein. European Journal of Nuclear Medicine and Molecular Imaging, 2010, 37, 1926-1934.	6.4	46
120	Recombinant, ETAâ€²-based CD64 immunotoxins: improved efficacy by increased valency, both in vitro and in vivo in a chronic cutaneous inflammation model in human CD64 transgenic mice. British Journal of Dermatology, 2010, 163, 279-286.	1.5	21
121	High efficiency non-viral transfection of retinal and iris pigment epithelial cells with pigment epithelium-derived factor. Gene Therapy, 2010, 17, 181-189.	4.5	21
122	A Human Recombinant Autoantibody-Based Immunotoxin Specific for the Fetal Acetylcholine Receptor Inhibits Rhabdomyosarcoma Growth In Vitro and in a Murine Transplantation Model. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-11.	3.0	17
123	Fast detection of air contaminants using immunobiological methods. Proceedings of SPIE, 2009, , .	0.8	1
124	Development of Novel, Highly Cytotoxic Fusion Constructs Containing Granzyme B: Unique Mechanisms and Functions. Current Pharmaceutical Design, 2009, 15, 2676-2692.	1.9	32
125	Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer, 2009, 9, 200.	2.6	29
126	Site-Specific, Covalent Labeling of Recombinant Antibody Fragments via Fusion to an Engineered Version of 6-O-Alkylguanine DNA Alkyltransferase. Bioconjugate Chemistry, 2009, 20, 1010-1015.	3.6	48

#	Article	IF	Citations
127	Recombinant bispecific single chain antibody fragments induce FcÎ³-receptor-mediated elimination of CD30+ lymphoma cells. Cancer Letters, 2009, 282, 187-194.	7.2	10
128	Targeted Restoration of Down-regulated DAPK2 Tumor Suppressor Activity Induces Apoptosis in Hodgkin Lymphoma Cells. Journal of Immunotherapy, 2009, 32, 431-441.	2.4	38
129	Fcγ Receptor 1 (CD64), a Target Beyond Cancer. Current Pharmaceutical Design, 2009, 15, 2712-2718.	1.9	20
130	Editorial [Hot Topic: Recombinant Immunotoxins â€“ The Next Generation (Executive Editor: Stefan) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.9	2
131	Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery. Recent Patents on Anti-Cancer Drug Discovery, 2009, 4, 1-8.	1.6	17
132	Immunokinases, a Novel Class of Immunotherapeutics for Targeted Cancer Therapy. Current Pharmaceutical Design, 2009, 15, 2693-2699.	1.9	19
133	Depletion of autoreactive B-lymphocytes by a recombinant myelin oligodendrocyte glycoprotein-based immunotoxin. Journal of Neuroimmunology, 2008, 195, 28-35.	2.3	23
134	Eukaryotic expression and secretion of EGFP-labeled annexin A5. Protein Expression and Purification, 2008, 58, 325-331.	1.3	18
135	Granzyme B-H22(scFv), a human immunotoxin targeting CD64 in acute myeloid leukemia of monocytic subtypes. Molecular Cancer Therapeutics, 2008, 7, 2924-2932.	4.1	89
136	Cell-Specific Induction of Apoptosis by Rationally Designed Bivalent Aptamer-siRNA Transcripts Silencing Eukaryotic Elongation Factor 2. Current Cancer Drug Targets, 2008, 8, 554-565.	1.6	103
137	Small Cleavable Adapters Enhance the Specific Cytotoxicity of a Humanized Immunotoxin Directed Against CD64-positive Cells. Journal of Immunotherapy, 2008, 31, 370-376.	2.4	50
138	Immunodetection of Venturia inaequalis Ascospores with Phage Antibodies. Journal of Phytopathology, 2007, 155, 170-177.	1.0	4
139	Characterization of photosynthetically active duckweed (Wolffia australiana) in vitro culture by Respiration Activity Monitoring System (RAMOS). Biotechnology Letters, 2007, 29, 971-977.	2.2	13
140	In contrast to specific B cells, human basophils are unaffected by the toxic activity of an allergen toxin due to lack of internalization of immunoglobulin E-bound allergen. Clinical and Experimental Allergy, 2006, 36, 531-542.	2.9	4
141	Generation of human antibody fragments against Streptococcus mutans using a phage display chain shuffling approach. BMC Biotechnology, 2005, 5, 4.	3.3	11
142	Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. International Journal of Molecular Medicine, 2005, 15, 305.	4.0	13
143	Recombinant soluble human FcÎ³ receptor I with picomolar affinity for immunoglobulin G. Biochemical and Biophysical Research Communications, 2005, 338, 1811-1817.	2.1	21
144	Antigen-specific targeting and elimination of EBV-transformed B cells by allergen toxins. Journal of Allergy and Clinical Immunology, 2005, 116, 910-915.	2.9	8

#	Article	IF	Citations
145	Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice. International Journal of Molecular Medicine, 2005, 15, 305-13.	4.0	34
146	Anti-CD30-scFv-Fc-IL-2 antibody-cytokine fusion protein that induces resting NK cells to highly efficient cytolysis of Hodgkin's lymphoma derived tumour cells. International Journal of Cancer, 2004, 110, 386-394.	5.1	19
147	Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA? against human lymphomasin vivo. International Journal of Cancer, 2004, 111, 568-574.	5.1	22
148	Secretion of functional anti-CD30-angiogenin immunotoxins into the supernatant of transfected 293T-cells. Protein Expression and Purification, 2003, 28, 211-219.	1.3	58
149	A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. International Journal of Molecular Medicine, 2003, 11, 523.	4.0	4
150	The recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA' suppresses growth of a highly metastatic pancreatic carcinoma cell line. International Journal of Oncology, 2003, 23, 1179-86.	3.3	21
151	A novel approach for immunization, screening and characterization of selected scFv libraries using membrane fractions of tumor cells. International Journal of Molecular Medicine, 2003, 11, 523-7.	4.0	9
152	Recombinant CD64-specific single chain immunotoxin exhibits specific cytotoxicity against acute myeloid leukemia cells. Cancer Research, 2003, 63, 8414-9.	0.9	47
153	Transient transformation of Wolffia columbiana by particle bombardment. Aquatic Botany, 2002, 72, 175-181.	1.6	20
154	Photodynamic Therapy Mediated Induction of Accelerated Re-endothelialisation Following Injury to the Arterial Wall: Implications for the Prevention of Postinterventional Restenosis. European Journal of Vascular and Endovascular Surgery, 2002, 24, 166-175.	1.5	16
155	Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin. International Journal of Cancer, 2002, 98, 210-215.	5.1	24
156	Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Annals of Hematology, 2002, 81, 258-266.	1.8	19
157	The in vitro anti-inflammatory effects of recombinant anti-CD25 immunotoxin on lamina propria T cells of patients with inflammatory bowel disease are not sufficient to cure experimental colitis in mice. International Journal of Colorectal Disease, 2002, 17, 77-84.	2.2	5
158	Technology evaluation: BL22, NCI. Current Opinion in Molecular Therapeutics, 2002, 4, 72-5.	2.8	4
159	Human angiogenin fused to human CD30 ligand (Ang-CD30L) exhibits specific cytotoxicity against CD30-positive lymphoma. European Journal of Cancer, 2001, 37, S12.	2.8	8
160	Bispecific antibody-mediated destruction of Hodgkinâ€™s lymphoma cells. Journal of Immunological Methods, 2001, 248, 113-123.	1.4	30
161	Quantification of Residual Tumor Cells in Monoclonal B-cell Lymphoma. , 2001, , 219-229.		0
162	Recombinant anti-CD25 immunotoxin RFT5(SCFV)-ETA' demonstrates successful elimination of disseminated human Hodgkin lymphoma in SCID mice. , 2000, 86, 718-724.		24

#	Article	IF	Citations
163	Tumorvakzine: Immuntherapie im Jahr 2000. Onkologe, 2000, 6, S31-S35.	0.7	0
164	Ki-4(scFv)â€“ETAâ€², a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood, 2000, 95, 3909-3914.	1.4	79
165	Compatible-Solute-Supported Periplasmic Expression of Functional Recombinant Proteins under Stress Conditions. Applied and Environmental Microbiology, 2000, 66, 1572-1579.	3.1	169
166	Combining phage display and screening of cDNA expression libraries: a new approach for identifying the target antigen of an scFv preselected by phage display 1 1Edited by J. Wells. Journal of Molecular Biology, 2000, 301, 751-757.	4.2	12
167	Ki-4(scFv)â€“ETAâ€², a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice. Blood, 2000, 95, 3909-3914.	1.4	5
168	An anti-CD30 single-chain Fv selected by phage display and fused to Pseudomonas exotoxin A (Ki-4(scFv)-ETAâ€™) is a potent immunotoxin against a Hodgkin-derived cell line. British Journal of Cancer, 1999, 80, 1214-1222.	6.4	70
169	A new series of pET-derived vectors for high efficiency expression of Pseudomonas exotoxin-based fusion proteins. Gene, 1999, 229, 145-153.	2.2	38
170	Non-HodgkinÊ¼s Lymphoma. BioDrugs, 1997, 8, 216-234.	4.6	2
171	A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients With Refractory Hodgkin's Lymphoma. Blood, 1997, 89, 403-410.	1.4	148
172	A regeneration protocol for sunflower (Helianthus annuus L.) protoplasts. Plant Cell Reports, 1996, 15, 742-745.	5.6	29
173	9 Future treatment strategies: fact or fiction?. Best Practice and Research: Clinical Haematology, 1996, 9, 573-593.	1.1	3
174	Potent anti-tumor effects of an anti-CD24 ricin A-chain immunotoxininin vitro and in a disseminated human Burkitt's lymphoma model in SCID mice. , 1996, 66, 526-531.		12
175	A regeneration protocol for sunflower (Helianthus annuus L.) protoplasts. Plant Cell Reports, 1996, 15, 742-745.	5.6	7
176	Selection and enrichment of differentially labeled plant protoplasts. Journal of Proteomics, 1994, 29, 83-86.	2.4	3
177	Plantlet Regeneration from Electrostimulated Protoplasts of Sunflower (Helianthus annuusL.). Botanica Acta, 1993, 106, 220-222.	1.6	13
178	Somatic Hybrids of Sunflower (Helianthus annuusL.) Identified at the Callus Stage by Isoenzyme Analysis. Botanica Acta, 1993, 106, 100-102.	1.6	10
179	Rapid detection of different human anti-HCV immunoglobulins on electrical biochips. Antibody Technology Journal, 0, , 23.	0.0	1